Recursion Pharmaceuticals Reports Q2 2025 Financial Results

Recursion Pharmaceuticals, Inc ( (RXRX) ) has released its Q2 earnings. Here is a breakdown of the information Recursion Pharmaceuticals, Inc presented to its investors.

Recursion Pharmaceuticals, Inc. is a clinical stage TechBio company that leverages advanced technology to decode biology and improve lives, primarily operating in the biotechnology sector.

In its latest earnings report, Recursion Pharmaceuticals shared significant business updates and financial results for the second quarter of 2025, highlighting a milestone achievement with Sanofi and advancements in their clinical pipeline.

The company reported total revenue of $19.2 million, an increase from the previous year, primarily driven by collaboration agreements. However, research and development expenses rose significantly to $128.6 million, contributing to a net loss of $171.9 million for the quarter. Key developments include progress in clinical trials for REC-1245 and REC-617, with promising early data, and a milestone payment from Sanofi for an immunology program.

Recursion continues to expand its platform capabilities, with Recursion OS 2.0 driving program development across biology, chemistry, and clinical sectors. The company maintains a strong cash position, with $533.8 million in cash and equivalents, projecting a cash runway into the fourth quarter of 2027.

Looking ahead, Recursion remains focused on advancing its pipeline and partnerships, with potential for significant milestone payments and continued development of its proprietary platform to enhance drug discovery and development processes.